Cartilage-Hair Hypoplasia (CHH) Cell Models for Research

Cartilage-Hair Hypoplasia (CHH) is a rare autosomal recessive disorder with an estimated incidence of 1 in 20,000 to 1 in 100,000 live births, with higher prevalence among the Old Order Amish and Finnish populations. The condition is characterized by short stature, metaphyseal dysplasia, hypoplastic hair, and impaired cellular immunity, leading to increased susceptibility to infections and risk of malignancy. According to the National Institutes of Health (NIH), CHH is caused by mutations in the RMRP gene, which encodes the RNA component of the mitochondrial RNA-processing endoribonuclease. The clinical severity varies, and patients may experience life-threatening complications such as severe combined immunodeficiency (SCID) or lymphoma. The 5-year survival rate is not well-defined due to rarity, but early diagnosis and management improve outcomes. Research on CHH is significant for understanding ribosome biogenesis, cell cycle regulation, and immune function, and for developing targeted therapies.

CHH serves as an excellent model for studying the molecular mechanisms of skeletal dysplasia, immunodeficiency, and cancer predisposition. The disease is caused by mutations in a non-coding RNA gene, providing unique insights into the role of non-coding RNAs in human disease. Public datasets, such as those from the NCBI Gene and ClinVar, provide comprehensive information on RMRP mutations and their clinical associations. Open questions include the precise molecular pathways linking RMRP dysfunction to the diverse clinical features, and the development of targeted therapies. Gene-edited cell models, such as RMRP knockout or knock-in cell lines, are invaluable for functional studies and drug discovery.

CHH is not primarily a cancer syndrome, but it predisposes to certain malignancies, particularly lymphoma and basal cell carcinoma. The major pathways involved include:

1. RMRP function in ribosome biogenesis: RMRP is a component of the RNase MRP complex, which processes pre-rRNA. Mutations lead to impaired ribosome assembly, affecting cell proliferation and growth.

2. Cell cycle regulation: RMRP interacts with the CDK inhibitor p21 and regulates cyclin-dependent kinase activity. Dysregulation contributes to uncontrolled cell growth.

3. Immune dysfunction: RMRP mutations affect T-cell and B-cell function, leading to immunodeficiency and increased risk of infections and cancer.

4. Telomere maintenance: RMRP is involved in telomere length regulation, and mutations may lead to genomic instability.

Data from ClinVar and NCBI Gene.

RMRP mutations affect multiple signaling networks:

• • PI3K/AKT pathway: RMRP regulates cell survival and proliferation; mutations lead to altered signaling.
• • p53 pathway: RMRP interacts with p53, affecting apoptosis and cell cycle arrest.
• • Wnt signaling: RMRP may influence Wnt pathway, contributing to skeletal abnormalities.
• • Immune signaling: RMRP affects T-cell receptor signaling and cytokine production.

Organoids derived from patient tissues can recapitulate the skeletal and immune phenotypes, providing a more physiologically relevant model for studying CHH.

• • Genetically engineered mouse models (GEMMs) with RMRP mutations have been developed to study the disease.
• • Patient-derived xenografts (PDX) of CHH-associated tumors can be used for drug testing.
• • Induced pluripotent stem cell (iPSC) models from patients can differentiate into chondrocytes and immune cells for mechanistic studies.

CRISPR-Cas9 technology enables the generation of isogenic cell lines with precise RMRP mutations. For example:

• • RMRP knockout cell lines: These lines have complete loss of RMRP function, mimicking severe CHH. They are useful for studying the impact on ribosome biogenesis and cell proliferation.
• • RMRP knock-in cell lines: These lines carry specific patient mutations (e.g., 70A>G) and allow for studying genotype-phenotype correlations.
• • Reporter cell lines: RMRP promoter-reporter lines can be used to monitor gene expression in response to drugs.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing consistent and validated tools. These models are essential for drug discovery, target validation, and functional genomics.

Gene-edited cell lines are used to validate the function of RMRP and its interacting partners. For example, RMRP knockout lines can be used to identify downstream targets via transcriptomics and proteomics. Knock-in lines with specific mutations can reveal allele-specific effects on cellular pathways.

Isogenic pairs (wild-type vs. RMRP knockout) are ideal for high-throughput screening of compounds that selectively target RMRP-deficient cells. These models can also be used to study drug resistance mechanisms, as RMRP mutations may affect drug metabolism and sensitivity.

CRISPR-based synthetic lethality screens using RMRP knockout lines can identify genes that are essential only in the absence of RMRP, providing potential therapeutic targets and biomarkers. For example, inhibitors of such synthetic lethal partners could be developed as targeted therapies for CHH-associated cancers.